Life Sciences & Biotechnology
Title : | Preclinical Implication of liposomal hydrogel loaded dual drug Metadoxine and PDE-5 Inhibitor for transdermal delivery to target myofibroblast to ameliorate fibrosis |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Prof. Vikas Agarwal, sanjay Gandhi Postgraduate Institute Of Medical sciences, Uttar Pradesh |
Timeline Start Year : | 2023 |
Timeline End Year : | 2026 |
Contact info : | vikasagr@yahoo.com |
Equipments : | Franz Diffusion Cell Apparatus |
Details
Executive Summary : | Fibrosis is a condition caused by chronic inflammation, vasculopathy, and excessive extracellular matrix deposition in the skin and internal organs. There is currently no available treatment for fibrosis, with TGF-β1 activation being the hallmark of fibrotic pathogenesis. serotonin (5-HT) released from platelets has been implicated in fibrosis in carcinoid tumors and animal models of skin fibrosis. The phosphodiesterase-5 inhibitor has been reported to control fibrosis by activating cGMP-mediated protein kinase G activation, inhibiting canonical and non-canonical signaling pathways. The study aims to synthesize a transdermally deliverable dual drug, Tadalafil and Metadoxine, targeting myofibroblast receptor AV-Integrin through surface modification of RGD through liposomal hydrogel. The drug will be synthesized using a thin-film hydration method and incorporated in hydrogel for transdermal delivery. The anti-fibrotic efficacy of the transdermal drug will be evaluated on the HADF cell line and dermal scleroderma induced sKH-1 mouse model. Topical administration is expected to be an appealing alternative to oral routes, suppressing toxicity and reducing dose concentration. |
Co-PI: | Dr. Durga Prasanna Misra, sanjay Gandhi Postgraduate Institute Of Medical sciences, Lucknow, Uttar Pradesh-226014, Dr. satyakam Patnaik, CsIR- Indian Institute Of Toxicology Research, Lucknow, Uttar Pradesh-226001 |
Total Budget (INR): | 44,18,740 |
Organizations involved